This study investigated the potential of an innovative combinational therapy utilizing antimicrobial blue light (aBL) and cold atmospheric plasma (CAP) against Staphylococcus aureus, a clinically challenging gram-positive bacterium. For planktonic S. aureus, sequential treatment (1-3 min CAP followed by 270 J/cm2 aBL) demonstrated an increase of 3- to 6- log10CFU reduction compared to aBL alone, while simultaneous treatment (concurrent 90 J/cm2 aBL and 25 min CAP) led to an increase of 7-log10CFU reduction. For biofilms, a remarkable CFU reduction of 6.5- to 7- log10 was observed for sequential treatment (3-5 min CAP followed by 432 J/cm2 aBL) and a 3-log10CFU reduction for simultaneous treatment (concurrent application 108 J/cm2 aBL and 30 min CAP). These findings highlight the unprecedented efficacy of the aBL + CAP combinational therapy in enhancing the potency against S. aureus, offering a promising approach to overcome antibiotic resistance.
|